Private company

Omega Therapeutics, Inc.

In its 2024 annual report the company says: “Omega Therapeutics is a clinical-stage biotechnology company pioneering a new class of programmable epigenomic mRNA medicines. We have deciphered the three-dimensional architecture of the human genome.”3 It is headquartered in Cambridge, Massachusetts.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersCambridge, Massachusetts1
  • Incorporated inDE2
  • Business address140 First Street, Suite 501, Cambridge, Ma 021412
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Omega Therapeutics is a clinical-stage biotechnology company pioneering a new class of programmable epigenomic mRNA medicines. Our OMEGA platform harnesses the power of epigenetics and our deep understanding of genomic architecture to precisely target and controllably modulate gene expression at the pre-transcriptional level to treat or cure diseases. We have deciphered the three-dimensional architecture of the human genome. Genes and their accompanying regulators are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains, or IGDs. IGDs are the fundamental structural and functional units of gene control and cell differentiation and act as nature's innate control system for gene expression. Most diseases are caused by aberrant gene expression rooted in alterations in IGDs. The OMEGA platform has enabled us to systematically identify and validate t…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-3240.5%Operating margin4
-3148.9%Net margin4
49.3%Revenue growth, 20234
-167.9%Return on equity4
0.26×Debt to equity4
-$94.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$77.2M

Out of $3.1M in revenue.4 The company lost money this year.

Financial statements

Revenue54$3.1M in 2023+2049% since 2021
0$1.0M$2.0M$3.0M$4.0M2021: $144.0K$144.0K20212022: $2.1M$2.1M2022+1340%2023: $3.1M$3.1M2023+49%
Operating income564-$100.3M in 2023+250% since 2020
-$150.0M-$100.0M-$50.0M02020: -$28.6M-$28.6M20202021: -$66.0M-$66.0M2021+131%2022: -$102.8M-$102.8M2022+56%2023: -$100.3M-$100.3M2023−2%
Net income564-$97.4M in 2023+231% since 2020
-$150.0M-$100.0M-$50.0M02020: -$29.4M-$29.4M20202021: -$68.3M-$68.3M2021+132%2022: -$102.7M-$102.7M2022+50%2023: -$97.4M-$97.4M2023−5%
Fiscal year20192020202120222023
Revenue$144.0K5$2.1M4$3.1M4
Research and development$21.1M5$47.9M6$81.2M4$77.2M4
Operating expenses$66.2M6$104.8M4$103.4M4
Operating income-$28.6M5-$66.0M6-$102.8M4-$100.3M4
Interest$777.0K5$910.0K5
Income tax$05$06$04$04
Net income-$29.4M5-$68.3M6-$102.7M4-$97.4M4
Earnings per share-$3.056-$2.144-$1.804
Earnings per share (diluted)-$3.056-$2.144-$1.804
Shares (weighted, basic)22.4M shares647.9M shares454.0M shares4
Shares (weighted, diluted)22.4M shares647.9M shares454.0M shares4

Compare Omega Therapeutics, Inc. with another company

Corporate structure

Omega Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Omega Therapeutics, Inc.

  • FMR LLC Filed SCHEDULE 13G/A on Omega Therapeutics, Inc., latest Mar 7, 2025 (6 filings since Feb 9, 2022)
  • Flagship V VentureLabs Rx Fund, L.P. Filed SCHEDULE 13D/A on Omega Therapeutics, Inc., latest Feb 5, 2025
  • Flagship Ventures Fund V, L.P. Filed SCHEDULE 13D/A on Omega Therapeutics, Inc., latest Dec 31, 2024 (2 filings since Feb 27, 2023)
  • HarbourVest Partners L.P. Filed SC 13G/A on Omega Therapeutics, Inc., latest Feb 9, 2024 (2 filings since Feb 14, 2022)
  • Omega Therapeutics, Inc. Cambridge, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Omega Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$11.4M4 Dec 31, 2023$9.6M4 Dec 31, 2022+18.4%
Accumulated depreciation$6.1M4 Dec 31, 2023$5.4M4 Dec 31, 2022+12.0%
Property and equipment, net$5.3M4 Dec 31, 2023$4.2M4 Dec 31, 2022+26.6%
Operating-lease assets (leased space)$108.7M4 Dec 31, 2023$3.7M4 Dec 31, 2022+2864.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$68.4M4 Dec 31, 2023$70.6M4 Dec 31, 2022−3.1%
Marketable securities, current$5.0M4 Dec 31, 2023$54.1M4 Dec 31, 2022−90.8%

Leadership

Who has led Omega Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mahesh Karande2021–2024

President

  1. Mahesh Karande2021–2024

Chief financial officer

  1. Roger Sawhney2021–2022
  2. Joshua Reed2022–2024
2025
Board members and other officers (20)

Timeline

  1. Feb 24, 20258-K Entered a material agreement; Listing notice or transfer32
  2. Feb 14, 20258-K Entered a material agreement; Bankruptcy or receivership; New debt or obligation33
  3. Feb 3, 20258-K Entered a material agreement; Ended a material agreement; New debt or obligation34
  4. Jan 28, 20258-K Executive or director change35
  5. Jan 17, 20258-K Debt or obligation accelerated36
  6. Jan 10, 20258-K Executive or director change37
  7. Dec 31, 20248-K Executive or director change; Other events38
  8. Dec 6, 20248-K Executive or director change39
  9. Nov 14, 20248-K Entered a material agreement; Executive or director change; Other events40
  10. Oct 4, 20248-K Executive or director change41
  11. Aug 30, 20248-K Entered a material agreement42
  12. Aug 6, 20248-K Results of operations43
  13. Jul 29, 2021New chief executive Mahesh Karande becomes CEO10

Calendar

When it reported results

  1. Aug 6, 2024Reported quarterly or annual results43
  2. May 6, 2024Reported quarterly or annual results44
  3. Mar 28, 2024Reported quarterly or annual results45
  4. Nov 9, 2023Reported quarterly or annual results46
  5. Aug 3, 2023Reported quarterly or annual results47
  6. May 4, 2023Reported quarterly or annual results48
  7. Mar 1, 2023Reported quarterly or annual results49
  8. Nov 8, 2022Reported quarterly or annual results50

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

166 filings to the SEC since October 2021: 4 annual reports, 10 quarterly reports, 42 major events, 78 insider forms, 11 large holders, 21 other. The latest 20:

  1. Mar 31, 202515-12G EDGAR
  2. Mar 25, 2025EFFECT EDGAR
  3. Mar 21, 2025POS AM EDGAR
  4. Mar 21, 2025S-8 POS EDGAR
  5. Mar 20, 202525 EDGAR
  6. Mar 7, 2025SCHEDULE 13G/A EDGAR
  7. Feb 24, 20258-K EDGAR
  8. Feb 14, 20258-K EDGAR
  9. Feb 5, 2025144 EDGAR
  10. Feb 5, 2025SCHEDULE 13D/A EDGAR
  11. Feb 4, 20253 EDGAR
  12. Feb 3, 20258-K EDGAR
  13. Jan 28, 20258-K EDGAR
  14. Jan 17, 20258-K EDGAR
  15. Jan 10, 20258-K EDGAR
  16. Dec 31, 20248-K EDGAR
  17. Dec 31, 2024SCHEDULE 13D/A EDGAR
  18. Dec 6, 20248-K EDGAR
  19. Dec 5, 20244 EDGAR
  20. Dec 5, 20243 EDGAR

The 166 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 1 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 2, 2023Young Richard ADirectorSale5,000$8.00$40.0KForm 4
May 1, 2023Young Richard ADirectorSale5,000$8.00$40.0KForm 4
Apr 6, 2023Young Richard ADirectorSale5,000$8.00$40.0KForm 4
Mar 17, 2023Young Richard ADirectorSale10,000$8.00$80.0KForm 4
Feb 27, 2023Flagship Pioneering Inc.10% ownerBuy3,323,310$5.78$19.2MForm 4
Jan 10, 2023Young Richard ADirectorSale20,000$8.00$160.0KForm 4
Sep 14, 2022Young Richard ADirectorSale10,000$8.00$80.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Omega Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROmega Therapeutics, Inc.1
  • CIK0001850838
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address140 First Street, Suite 501, Cambridge, MA 021411
  • Phone(617) 949-43601
  • Shares outstanding55,366,213 as of Nov 8, 20248
  • Public float$140.2M as of Jun 30, 20234
  • On EDGAR sinceMay 10, 20211
  • Filings210 in all: 4 (70), 8-K (43), 3 (28), 10-Q (11), CORRESP (5), SC 13G/A (5), 10-K (3), 144 (3)1
    All 37 form types

    DEF 14A (3), DEFA14A (3), EFFECT (3), UPLOAD (3), 424B5 (2), DRS/A (2), SC 13G (2), SCHEDULE 13D/A (2), SEC STAFF LETTER (2), 10-K/A (1), 15-12G (1), 25 (1), 4/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRSLTR (1), POS AM (1), PRE 14A (1), S-1 (1), S-1/A (1), S-3 (1), S-8 (1), S-8 POS (1), SC 13D (1), SC 13D/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2024
    Quarterly report (10-Q) Nov 14, 2024
    Proxy statement (DEF 14A) Apr 29, 2024
    Latest 8-K (8-K) Feb 24, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54